COX-2 inhibitors as cancer treatment: will they be the new warfarin or trastuzumab?
Liebmann
James
J
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D000068878:Trastuzumab; D014859:Warfarin / Q000494:pharmacology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D014859:Warfarin; D000068878:Trastuzumab